All In Biotech

Drug Trial Radar · NCT04146610

Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors

A Phase Ia, Multicenter, Open and Dose-increasing Study of DP303c to Evaluate the Safety , Pharmacokinetics, Immunogenicity and Antitumor Activity of Subjects With HER2-Positive Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Planned (sponsor's estimate)

Start

Nov 2019

Primary completion

Jun 2021

Study completion Jun 2021

Sponsor

Sponsor type
Industry
First posted
Oct 31, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase Ia, multicenter, open and dose-increasing study of DP303c to evaluate the safety , pharmacokinetics, immunogenicity and antitumor activity of subjects with HER2-positive advanced solid tumors.

Conditions

  • Neoplasms

Interventions

  • an antibody drug conjugateDrug

    Multiple dose grouping

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximal Tolerance Dose (MTD) of Dp303cTime frame: The first treatment cycle 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Cancer Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.